Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Trial for AML Patients in CR2 Comparing 8Gy TBI /Fludarabine to Conditioning With TBI 12Gy/Cyclophosphamide

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with AML in second complete remission~* HLA-identical related (HLA \* A, B, and DR) or HLA-compatible unrelated donor with maximum of one Ag mismatch~* Ages 18-60 years~* Written informed consent from the patient~* Written informed consent from the donor~* No major organ dysfunction~Exclusion Criteria:~* Cardiac failure (New York Heart Association \[NYHA\] grade II-IV)~* Renal failure (creatinine \> 2.0 mg/dl)~* Hepatic failure (total bilirubin \> 3 mg/dl)~* Severe neurological/psychiatric disorder~* Previous allogeneic HSCT~* Contra-indications for used drugs~* HIV infection~* Non-compliance to processing of personal data according to the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- conditioning therapy with 12 Gy TBI / cyclophosphamide 120 (Type: ACTIVE_COMPARATOR): None
- conditioning therapy with 8 Gy TBI / fludarabine 120 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).